Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacytidine + Valproic Acid + ATRA in AML and High Risk MDS
NCT00339196Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, valproic acid, tretinoin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Assistance publique - Hôpitaux de Paris. Started Jul 2006; status: completed.
02
Drugs
azacitidinevalproic acidtretinoin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00339196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00339196.